Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
47 hedge funds and large institutions have $16.9M invested in Baudax Bio, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 15 closing their positions.
5,649% more call options, than puts
Call options by funds: $2.13M | Put options by funds: $37K
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
11% less funds holding
Funds holding: 53 → 47 (-6)
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
52% less capital invested
Capital invested by funds: $34.8M → $16.9M (-$17.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRC
North Run Capital
Boston,
Massachusetts
|
+$6.03M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.12M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$2.92M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.7M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
-$2.46M |
| 2 |
NM
Newtyn Management
New York
|
-$1.93M |
| 3 |
Renaissance Technologies
New York
|
-$1.86M |
| 4 |
NRCM
Northern Right Capital Management
Darien,
Connecticut
|
-$1.32M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$888K |
BXRX Hedge Fund Activity: Q1 2020 in Review
47 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q1 2020, worth a combined $16.9M — down 52% from $34.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of BXRX and 10 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 13 added.
The largest buyer was North Run Capital, adding an estimated $6.03M. The largest seller was Engine Capital Management, cutting an estimated $2.46M.
- 47 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q1 2020, down from 53 in Q4 2019.
- Funds reported $16.9M of Baudax Bio, Inc. Common Stock stock for Q1 2020, down 52% quarter-over-quarter.
- 10 funds opened new Baudax Bio, Inc. Common Stock positions in Q1 2020 and 15 closed out, a net change of -5 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q1 2020 was North Run Capital, an estimated $6.03M added.
- The largest Baudax Bio, Inc. Common Stock seller in Q1 2020 was Engine Capital Management, an estimated $2.46M sold.
Based on aggregated 13F filings for Q1 2020.